Advertisement

Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability

      Abstract

      3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to reduce cardiovascular morbidity and mortality by their actions on atherogenic lipid profiles and by pleiotropic effects. In this study, we have investigated the effect of a new statin, rosuvastatin (Crestor®), on sterol synthesis and the expression of metalloproteinases (MMPs) in human monocyte-derived macrophages (HMDM). Rosuvastatin dose-dependently inhibited sterol synthesis from acetate with an IC50 of 70 nM. In addition, MMP-7 levels were reduced in a dose-dependent manner with maximal inhibition of 50% (P<0.01) at 1 μM. Also, addition of isoprenoids such as farnesyl pyrophosphate (Fpp) or geranylgeranyl pyrophosphate (GGpp) fully overcame the inhibitory effect of rosuvastatin on MMP-7. Neither quantitative PCR nor transient transfection of HMDM with a luciferase reporter construct under the control of human MMP-7 promoter (2300 bp of the 5′ region on MMP-7 gene) showed a decrease in MMP-7 mRNA following treatment with rosuvastatin (10−6 M). However, the inhibitory effect of the statin occurred at the post-transcriptional level as determined by actinomycin D experiment. In conclusion, several studies have reported a high expression of active MMP-7 in human atherosclerotic plaques indicating a potential role in the weakening of the fibrous cap, predisposing it to rupture. The effect of rosuvastatin in reducing MMP-7 might protect fibrous caps from degradation and in turn stabilize atheromatous plaques.

      Abbreviations:

      MMP (matrix metalloproteinase), TIMP (tissue inhibitor of metalloproteinase), HMDM (human monocyte-derived macrophages)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ross R.
        Atherosclerosis: an inflammatory disease.
        N. Engl. J. Med. 1999; 340: 115-126
        • Davies M.J.
        • Thomas A.C.
        Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis characteristic of coronary atherosclerotic plaques underlying fatal occlusive thrombi.
        Br. Heart J. 1985; 53: 363-373
        • Moreno M.J.
        • Falk E.
        • Palacios I.F.
        • et al.
        Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture.
        Circulation. 1994; 90: 775-778
        • Lendon C.L.
        • Davies M.J.
        • Born G.V.R.
        • Richardson P.D.
        Atherosclerotic plaque caps are locally weakened when macrophage density is increased.
        Atherosclerosis. 1991; 87: 87-90
        • Galis Z.
        • Muszynski M.
        • Sukhova G.
        • et al.
        Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion.
        Circ. Res. 1994; 75: 181-189
        • Sakai N.
        • Santamarina-Fojo S.
        • Yamashita S.
        • Matsuzawa Y.
        • Brewer H.B.
        Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice selection.
        J. Lipid Res. 1996; 37: 2065-2073
        • Galis Z.
        • Sukhova G.
        • Lark M.
        • Libby P.
        Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
        J. Clin. Invest. 1994; 94: 2493-2503
        • Halpert I.
        • Sires U.I.
        • Roby J.D.
        • et al.
        Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme.
        Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 9748-9753
        • Galis Z.
        • Sukhova G.
        • Kranzhöfer R.
        • Clark S.
        • Libby P.
        Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases.
        Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 402-406
        • Rajavashisth T.B.
        Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators.
        Circulation. 1999; 99: 3103-3109
        • Vaughan C.J.
        • Murphy M.B.
        • Buckley B.M.
        Statins do more than just lower cholesterol.
        Lancet. 1996; 348: 1079-1082
        • Guijarro C.
        • Egido J.
        Modulation of the mevalonate pathway: potential mechanisms of vascular protection independent of cholesterol reduction.
        Cardiovasc. Risk Factors. 1997; 7: 29-33
        • Son J.W.
        • Koh K.K.
        • Ahn J.Y.
        • et al.
        Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease.
        Int. J. Cardiol. 2003; 88: 77-82
        • Koh K.K.
        • Son J.W.
        • Ahn J.Y.
        • et al.
        Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 2002; 22: e19-e23
        • Bellosta S.
        Direct vascular effects of HMG-CoA reductase inhibitors.
        Atherosclerosis. 1998; 137: S101-S109
        • Bernini F.
        • Didoni G.
        • Bonfadini G.
        • Bellosta S.
        • Fumagalli R.
        Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
        Atherosclerosis. 1993; 104: 19-26
        • Essig M.
        3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.
        Circ. Res. 1998; 83: 683-690
        • Colli S.
        Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 265-272
        • Bellosta S.
        • Via D.
        • Canavesi M.
        • et al.
        HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1671-1678
        • Ikeda U.
        • Shimpo M.
        • Ohki R.
        • et al.
        Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells.
        Hypertension. 2000; 36: 325-329
        • Wong B.
        • Lumma W.C.
        • Smith A.M.
        • et al.
        Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation.
        J. Leukoc. Biol. 2001; 69: 959-962
        • Crisby M.
        • Nordin-Fredriksson G.
        • Shah P.K.
        • et al.
        Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.
        Circulation. 2001; 103: 926-933
        • Aikawa M.
        • Rabkin E.
        • Sugiyama S.
        • et al.
        An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
        Circulation. 2001; 103: 276-283
        • Fukumoto Y.
        • Libby P.
        • Rabkin E.
        • et al.
        Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.
        Circulation. 2001; 103: 993-999
        • Nagashima H.
        • Aoka Y.
        • Sakomura Y.
        • et al.
        A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
        J. Vasc. Surg. 2002; 36: 158-163
        • Porter K.E.
        • Naik J.
        • Turner N.A.
        • et al.
        Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration.
        J. Vasc. Surg. 2002; 36: 150-157
        • Porter K.E.
        • Turner N.A.
        Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9.
        Biochem. Soc. Trans. 2002; 30: 120-126
        • Luan Z.
        • Chase A.J.
        • Newby A.C.
        Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
        Arterioscler. Thromb. Vasc. Biol. 2003; 23: 769-775
        • Takeuchi S.
        Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC.
        Biochem. Biophys. Res. Commun. 2000; 269: 97-102
        • Bourcier T.
        • Libby P.
        HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 556-562
        • Blasetto J.W.
        • Stein E.A.
        • Brown W.V.
        • Chitra R.
        • Raza A.
        Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
        Am. J. Cardiol. 2003; 91 ([discussion 10C]): 3C-10C
        • Schuster H.
        Rosuvastatin—a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10–40 mg doses in dyslipidemic patients.
        Cardiology. 2003; 99: 126-139
        • Stalker T.
        • Lefer A.
        • Scalia R.
        A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
        Br. J. Pharmacol. 2001; 133: 406-412
        • Laufs U.
        • Gertz K.
        • Dirnagl U.
        • et al.
        Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice.
        Brain Res. 2002; 942: 23-30
        • Taylor-Jones J.M.
        • McGehee R.E.
        • Rando T.A.
        • et al.
        Activation of an adipogenic program in adult myoblasts with age.
        Mech. Ageing Dev. 2002; 123: 649-661
        • de Winther M.P.
        • van Dijk K.W.
        • van Vlijmen B.J.
        • et al.
        Macrophage specific overexpression of the human macrophage scavenger receptor in transgenic mice, using a 180-kb yeast artificial chromosome, leads to enhanced foam cell formation of isolated peritoneal macrophages.
        Atherosclerosis. 1999; 147: 339-347
        • Dentan C.
        • Lesnik P.
        • Chapman M.J.
        • Ninio E.
        Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis.
        Eur. J. Biochem. 1996; 236: 48-55
        • Gaire M.
        • Magbanua Z.
        • McDonnell S.
        • et al.
        Structure and expression of the human gene for the matrix metalloproteinase matrilysin.
        J. Biol. Chem. 1994; 269: 2032-2040
        • Bellosta S.
        Pleiotropic effects of statins in atherosclerosis and diabetes.
        Diabetes Care. 2000; 23: B72-B78
        • Bienzle D.
        • Abrams-Ogg A.C.
        • Kruth S.A.
        • et al.
        Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation.
        Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 350-354
        • Brown M.S.
        • Goldstein J.L.
        Atherosclerosis. Scavenging for receptors.
        Nature. 1990; 343: 508-509
        • Casey P.J.
        Protein lipidation in cell signaling.
        Science. 1995; 268: 221-225
        • Seabra M.C.
        • Brown M.S.
        • Goldstein J.L.
        Retinal degeneration in choroidermia: deficiency of rab geranylgeranyl transferase.
        Science. 1993; 259: 377-381
        • Bond M.
        • Baker A.H.
        • Newby A.C.
        Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts.
        Biochem. Biophys. Res. Commun. 1999; 264: 561-567
        • Chase A.J.
        • Bond M.
        • Crook M.F.
        • Newby A.C.
        Role of nuclear factor-κB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo.
        Arterioscler. Thromb. Vasc. Biol. 2002; 22: 765
        • Brown P.D.
        • Bloxidge R.E.
        • Anderson E.
        • Howell A.
        Expression of activated gelatinase in human invasive breast carcinoma.
        Clin. Exp. Metastasis. 1993; 11: 183-189
        • Zempo N.
        • Koyama N.
        • Kenagy R.D.
        • Lea H.J.
        • Clowes A.W.
        Regulation of vascular smooth muscle cell migration and proliferation in vitro and injured rat arteries by a synthetic matrix metalloproteinase inhibitor.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 28-33